CompuMed regains OsteoGram rights

Article

Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit

Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit Merck subsidiary that had licensed the technology in 1995 (SCAN 9/13/95). Manhattan Beach, CA-based CompuMed reported that the OsteoGram Analysis Center generated a disappointingly small stream of royalty income.

BMI will return the rights to the OsteoGram technology at no cost to CompuMed, and will discontinue operating the OsteoGram Analysis Center on February 28, according to CompuMed. The company is considering distribution options such as new licensing revenues, as well as worldwide marketing of OsteoGram.

Related Videos
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2023 MJH Life Sciences

All rights reserved.